Drugs / Oseltamivir
Oseltamivir
also known as
Tamiflu · oseltamivir phosphate · Agucort · Ebilfumin · GS 4104 · GS-4071 ETHYL ESTER · HEC116094 · Oseltamivir (as phosphate) · +8 more
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | TAMIFLU | — | 2000-11-17 – 2019-08-02 | fda.gov ↗ |
| Approved | EU (EMA) | Tamiflu | — | 2002-06-20 | europa.eu ↗ |
| Approved | US (FDA) | TAMIFLU | — | 1999-10-27 | fda.gov ↗ |
Trials 73 · started per year
today
US approved 1999
EU approved 2002
1
1
4
5
4
11
7
7
3
1
3
4
4
1
1
8
3
3
2
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 124 trials | ||||||
| Phase 1 | NCT06057103 | Aug → Dec 2023 | — | Nanjing Zenshine Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05789342 | Feb → Sep 2023 | — | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05083325 | Oct 2021 | — | Laboratorios Andromaco S.A. | Completed | No outcome recorded |
| Phase 1 | NCT04982913 | Aug 2021 → Oct 2022 | influenza | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05108051 | Nov 2020 → Mar 2021 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03023852 | Feb → Apr 2017 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT02888327 | Jul 2016 → May 2017 | influenza | Alios Biopharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02262715 | Jul → Oct 2014 | — | Janssen Infectious Diseases BVBA | Completed | No outcome recorded |
| Phase 1 | NCT01715909 | Jan 2014 → Jun 2018 | influenza | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01902342 | Jul → Dec 2013 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01556633 | Mar → Jun 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01708369 | Feb → May 2012 | — | University of Tennessee | Completed | No outcome recorded |
| Phase 1 | NCT01053663 | Jan 2011 → Jan 2013 | influenza | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1 | NCT00988325 | Jan 2011 → Apr 2012 | influenza | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01033734 | Dec 2010 → Dec 2012 | influenza | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01049763 | Jan → Sep 2010 | — | South East Asia Infectious Disease Clinical Research Network | Completed | No outcome recorded |
| Phase 1 | NCT02717754 | Dec 2009 → May 2010 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01172847 | Aug 2009 → Feb 2010 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00921726 | Jul → Oct 2009 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00873886 | Apr 2009 → Sep 2010 | influenza, pregnancy disorder | University of Pittsburgh | Withdrawn | No outcome recorded |
| Phase 1 | NCT00540501 | Oct 2007 | — | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 1 | NCT00439530 | Nov 2006 → Apr 2007 | avian influenza | Mahidol University | Completed | No outcome recorded |
| Phase 1 | NCT00416962 | Aug → Dec 2006 | — | Novartis | Completed | No outcome recorded |
| Phase 1 | NCT02617784 | Oct 2001 → Jun 2002 | end stage renal failure | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02603952 | Dec 2015 → Dec 2016 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT01179919 | Jul → Sep 2010 | obesity disorder | Manjunath Prakash Pai | Completed | No outcome recorded |
| Phase 1/2 | NCT00391768 | Jan 2007 → Mar 2010 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT05648448 | Feb 2023 → Jan 2027 expected | influenza | University of Oxford | Recruiting | No outcome recorded |
| Phase 2 | NCT04516915 | Jun 2020 → May 2022 | COVID-19 | University Hospitals Coventry and Warwickshire NHS Trust | Completed | No outcome recorded |
| Phase 2 | NCT03903718 | Apr → Oct 2020 | influenza | MedImmune LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT02469298 | Jun 2015 → Apr 2016 | viral infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01146535 | Jan 2011 → Dec 2012 | influenza | Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01037634 | Mar 2010 → Mar 2012 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 2 | NCT01010087 | Nov 2009 → May 2011 | influenza | University of Manitoba | Terminated | No outcome recorded |
| Phase 2 | NCT00830323 | Jan → Aug 2009 | influenza | Hospices Civils de Lyon | Terminated | No outcome recorded |
| Phase 2 | NCT00453999 | Jul 2007 → Sep 2008 | influenza | BioCryst Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00334529 | Jun 2006 → Apr 2007 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01546935 | Dec 2012 → Dec 2014 | influenza | University of Oxford | Withdrawn | No outcome recorded |
| Phase 312 trials | ||||||
| Phase 3 | NCT07236814 | Nov 2025 → Mar 2027 expected | influenza | Capital Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT04338698 | Apr → Nov 2020 | COVID-19 | Shehnoor Azhar | Completed | No outcome recorded |
| Phase 3 | NCT04530422 | Apr → Jul 2020 | COVID-19 | Almaza Military Fever Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04261270 | Feb → May 2020 | COVID-19 | Tongji Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03520049 | Nov 2016 → Sep 2021 | autoimmune thrombocytopenia | Unity Health Toronto | Unknown | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | No outcome recorded |
| Phase 3 | NCT01231620 | Jan 2011 → Mar 2015 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01050257 | Jan 2010 → Sep 2012 | influenza | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00979667 | Oct 2009 → Aug 2010 | influenza, upper respiratory tract disorder | Chinese University of Hong Kong | Terminated | No outcome recorded |
| Phase 3 | NCT00949533 | Aug 2009 → Oct 2010 | influenza | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00707941 | May 2008 → Mar 2011 | influenza, pneumonia, viral exanthem | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 3 | NCT00545532 | Feb 2008 → May 2017 | influenza | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 418 trials | ||||||
| Phase 4 | NCT04684498 | Mar 2020 → Jun 2023 | ST-elevation myocardial infarction | Tongji Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04255017 | Feb → Jun 2020 | COVID-19 | Tongji Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04141917 | Nov 2019 → Mar 2021 | influenza | University of Washington | Terminated | No outcome recorded |
| Phase 4 | NCT02561169 | Dec 2015 → Mar 2016 | influenza | McMaster University | Terminated | No outcome recorded |
| Phase 4 | NCT02609399 | Nov 2015 → May 2017 | influenza | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT02282384 | Oct 2014 → Mar 2015 | influenza, lung disorder | McMaster University | Withdrawn | No outcome recorded |
| Phase 4 | NCT01456234 | Nov 2011 → May 2013 | influenza | Trial Management Group Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT01443806 | Jul 2011 → Dec 2012 | metabolic disease | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT01248715 | Nov 2010 → May 2016 | influenza, pneumonia | University of Louisville | Completed | No outcome recorded |
| Phase 4 | NCT01130636 | Jun 2010 → Jul 2012 | influenza | Pharmahungary Group | Completed | No outcome recorded |
| Phase 4 | NCT01032837 | Nov 2009 → Oct 2010 | influenza | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 4 | NCT00936013 | Aug 2009 → Jul 2011 | influenza | Capital Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT00935194 | Jul → Nov 2009 | influenza | Capital Medical University | Completed | No outcome recorded |
| Phase 4 | NCT02780622 | Feb → Jul 2008 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00412737 | Jan 2007 → May 2008 | influenza | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00436124 | Jan → Apr 2007 | influenza | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 4 | NCT00412555 | Dec 2006 → May 2007 | influenza | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00304434 | Feb 2005 → Feb 2007 | influenza | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT06762587 | Jan → Apr 2025 overdue | influenza, nosocomial infection | Capital Medical University | Not yet recruiting | No outcome recorded |
| — | NCT05008679 | Feb 2021 → Feb 2023 | heart failure | Tongji Hospital | Unknown | No outcome recorded |
| — | NCT04297462 | Nov 2016 → Mar 2020 | influenza | Centre of Postgraduate Medical Education | Unknown | No outcome recorded |
| — | NCT01314911 | Apr 2011 → Nov 2017 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00555893 | Jan 2008 → Feb 2011 | influenza | Marshfield Clinic Research Foundation | Completed | No outcome recorded |
Also used as a comparator or background therapy in 60 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04371601 Background | Mar 2020 → Dec 2021 | pneumonia | Fuzhou General Hospital | Unknown | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05818124 Comparator | Aug 2023 → Jun 2024 | influenza | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT04457609 Background | Jul → Aug 2020 | COVID-19, pneumonia | Indonesia University | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00867139 Comparator | Mar → Aug 2009 | influenza | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT04712539 Background | Oct 2021 → Feb 2028 expected | hematopoietic and lymphoid cell neoplasm, influenza | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT03394209 Background | Feb 2018 → Feb 2019 | influenza | Capital Medical University | Completed | No outcome recorded |
| Phase 2 | NCT03238612 Background | Jan 2018 → Jul 2020 | influenza | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 2 | NCT03212716 Background | Dec 2017 → May 2022 | influenza | University Hospital, Lille | Terminated | No outcome recorded |
| Phase 2 | NCT03028909 Background | Jul 2017 → Jul 2019 | — | MedImmune LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT02927431 Background | Jan → May 2017 | viral infectious disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT01965626 Comparator | Feb 2016 → May 2018 | thrombocytopenia | Shandong University | Completed | No outcome recorded |
| Phase 2 | NCT02532283 Background | Dec 2015 → Feb 2017 | influenza | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02293863 Background | Jan 2015 → May 2017 | influenza | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02342249 Comparator | Dec 2014 → May 2016 | influenza | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01980966 Comparator | Nov 2013 → Jun 2014 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01227967 Comparator | Sep 2010 → May 2016 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00979251 Comparator | Sep 2009 → May 2010 | influenza | Adamas Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00298233 Comparator | Feb 2006 → Jan 2010 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT02989012 Comparator | ? → Jul 2019 | influenza | Dalian Zhen-Ao Bio-Tech Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05170009 Comparator | Apr 2022 → Jan 2024 | influenza | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 322 trials | ||||||
| Phase 3 | NCT07496736 Comparator | Dec 2025 → Mar 2028 expected | influenza | University Medical Centre Ljubljana | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07229807 Comparator | Nov → Dec 2025 overdue | influenza | Guangdong Raynovent Biotech Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07357051 Comparator | Nov 2025 → Jan 2026 overdue | viral respiratory tract infection | Joincare Pharmaceutical Group Industry Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT07095257 Comparator | Oct 2025 → Jan 2026 | viral respiratory tract infection | Nanjing Zenshine Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT07113392 Comparator | Aug 2025 → Aug 2026 overdue | influenza | Jiangxi Kvvit Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06669351 Comparator | Oct 2024 → Jul 2025 | viral respiratory tract infection | Nanjing Zenshine Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT06774859 Comparator | Oct 2024 → May 2025 | influenza | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT03901001 Comparator | May 2023 → Oct 2025 | influenza | Chinese University of Hong Kong | Unknown | No outcome recorded |
| Phase 3 | NCT03900988 Comparator | May 2023 → Oct 2025 | influenza | Chinese University of Hong Kong | Unknown | No outcome recorded |
| Phase 3 | NCT04683406 Comparator | Dec 2020 → Apr 2023 | influenza | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT04349241 Comparator | Apr → Jun 2020 | COVID-19 | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT04558463 Comparator | Apr → Sep 2020 | COVID-19 | Indonesia University | Unknown | No outcome recorded |
| Phase 3 | NCT04381936 Comparator | Mar 2020 → Sep 2028 expected | pneumonia | University of Oxford | Recruiting | No outcome recorded |
| Phase 3 | NCT03629184 Comparator | Nov 2018 → Apr 2019 | influenza | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02949011 Comparator | Jan 2017 → Apr 2018 | influenza | Shionogi | Completed | No outcome recorded |
| Phase 3 | NCT02954354 Comparator | Dec 2016 → Apr 2017 | influenza | Shionogi | Completed | No outcome recorded |
| Phase 3 | NCT02662426 Comparator | Apr 2016 → Nov 2017 | influenza | The First Affiliated Hospital of Guangzhou Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT02369159 Comparator | Mar 2015 → Oct 2019 | influenza | BioCryst Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02108366 Background | Mar 2014 → Mar 2018 | influenza | The University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT01610245 Comparator | Mar 2013 → Mar 2015 | influenza | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00799760 Comparator | Dec 2008 → Nov 2009 | viral gastritis | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 3 | NCT00803595 Comparator | Nov 2008 → Mar 2009 | influenza | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 413 trials | ||||||
| Phase 4 | NCT05012189 Comparator | Aug 2021 → Dec 2023 | influenza | Insight Therapeutics, LLC | Unknown | No outcome recorded |
| Phase 4 | NCT04973462 Comparator | Aug → Sep 2021 | COVID-19 | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT04183725 Comparator | Dec 2019 → Jun 2021 | — | China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT03754686 Comparator | Feb 2019 → Jan 2022 | influenza | Rambam Health Care Campus | Unknown | No outcome recorded |
| Phase 4 | NCT01850446 Comparator | Feb 2015 → Apr 2018 | influenza | Materia Medica Holding | Completed | No outcome recorded |
| Phase 4 | NCT01690637 Comparator | Sep 2012 → Nov 2013 | influenza | Centers for Disease Control and Prevention | Terminated | No outcome recorded |
| Phase 4 | NCT02232945 Comparator | Apr 2012 → Aug 2016 | influenza | Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT01804946 Comparator | Feb 2011 → Apr 2014 | influenza | Materia Medica Holding | Completed | No outcome recorded |
| Phase 4 | NCT01249833 Comparator | Nov 2010 → Apr 2012 | influenza | Trial Management Group Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01052961 Comparator | Jan 2010 → Jun 2012 | influenza | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT01053377 Comparator | Dec 2009 → Dec 2013 | influenza | National Institute for Public Health and the Environment (RIVM) | Unknown | No outcome recorded |
| Phase 4 | NCT00980109 Comparator | Sep 2009 → Sep 2010 | influenza | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT00593502 Comparator | Feb 2008 → Jun 2009 | influenza | Hospital District of Southwestern Finland | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT03947411 Comparator | Mar 2019 → Mar 2020 | influenza | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| — | NCT03899571 Comparator | Jan 2019 → Mar 2020 | influenza | University Medical Centre Ljubljana | Completed | No outcome recorded |
| — | NCT03365336 Background | Feb → May 2018 | influenza | Composite Interceptive Med Science | Unknown | No outcome recorded |
| — | NCT01306773 Comparator | Dec 2009 → Dec 2010 | influenza | The University of Hong Kong | Completed | No outcome recorded |
| — | NCT00844155 Comparator | Mar → Jul 2009 | influenza | University of Manitoba | Withdrawn | No outcome recorded |
Press releases naming this drug 17 releases
| Date | Issuer | Release |
|---|---|---|
| 2011-02-07 | Gilead Sciences | Gilead Sciences Announces Notification of ANDA Filing for Tamiflu(R) gilead.com ↗ |
| 2005-11-16 | Gilead Sciences | Gilead and Roche End Tamiflu(R) Dispute; Expanded Collaboration Includes Gilead Role in Oversight of Manufacturing and Commercialization gilead.com ↗ |
| 2005-06-23 | Gilead Sciences | Gilead Delivers Termination Notice to Roche for Tamiflu Development and Licensing Agreement gilead.com ↗ |
| 2001-02-27 | Gilead Sciences | Roche Submits Oral Flu Drug Tamiflu for Regulatory Approval in Europe gilead.com ↗ |
| 2001-02-14 | Gilead Sciences | JAMA Study Reveals Roche's Tamiflu™ Effective In Protecting People Exposed to Influenza gilead.com ↗ |
| 2001-01-18 | Gilead Sciences | Pharmacy Shelves Make Room for Tamiflu™ Liquid for Kids gilead.com ↗ |
| 2000-12-14 | Gilead Sciences | Tamiflu™ Granted FDA Approval for Treatment of Flu in Children gilead.com ↗ |
| 2000-12-12 | Gilead Sciences | Roche's Oral Flu Drug Tamiflu™ Gets Approval in Japan gilead.com ↗ |
| 2000-11-20 | Gilead Sciences | Roche's Tamiflu™ Granted FDA Approval for the Prevention of Influenza gilead.com ↗ |
| 2000-09-18 | Gilead Sciences | New Tamiflu™ Data Shows Early Treatment Optimizes Benefit for Flu Sufferers gilead.com ↗ |
| 2000-08-02 | Gilead Sciences | Roche Submits Tamiflu for Regulatory Approval in Japan; First Oral Neuraminidase Inhibitor for the Treatment and Prevention of Influenza gilead.com ↗ |
| 2000-06-16 | Gilead Sciences | Roche Seeks to Broaden Tamiflu Treatment Indication with Pediatric Application gilead.com ↗ |
| 2000-05-26 | Gilead Sciences | Roche to Submit Additional Data on Tamiflu for the Treatment of Influenza to the European Regulatory Authorities gilead.com ↗ |
| 2000-05-23 | Gilead Sciences | Roche Seeks New Tamiflu Indication for the Prevention of Influenza gilead.com ↗ |
| 1999-11-08 | Gilead Sciences | Roche Announces New Data on Recently Approved Tamiflu™, First Pill to Treat the Most Common Strains of Influenza (A & B) gilead.com ↗ |
| 1999-10-27 | Gilead Sciences | Roche Receives FDA Approval Of TAMIFLU™, First Pill To Treat The Most Common Strains Of Influenza (A&B) gilead.com ↗ |
| 1999-09-24 | Gilead Sciences | First Approval of Roche’s Tamiflu™, a New Flu Treatment gilead.com ↗ |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 137 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | oseltamivir | “Participants will receive Oseltamivir 75 mg (1\*75 mg) oral capsule (reference) in Treatment D of Panel 2 and Oseltamivir 75 mg administered as JNJ-63623872/37.5 mg Oseltamivir...” NCT03023852 ↗129“An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir (Tamiflu®) in the Treatment of Infants 0 to <12 Months of Age With Confirmed...” NCT00988325 ↗ “Eligible patients in group 2 will receive oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to...” NCT04349241 ↗ “A triple-combination antiviral drug (TCAD) regimen consisting of amantadine (AMT), oseltamivir (OSL) and ribavirin (RBV) demonstrated good efficacy in an animal model.” PMID 23264438 ↗ Dec 2012 “The Safety, Tolerability, Pharmacokinetic, Food Effect Study and the interaction with Oseltamivir Phosphate Capsules of HEC116094 in Healthy Subjects” NCT04982913 ↗ “baloxavir for those aged ≥12 years, or oseltamivir for those aged \<12 years; pregnant; breastfeeding; liver disease; or are immunosuppressed” NCT04141917 ↗ “Oseltamivir is a first-line antiviral drug, especially in primary hospitals of military medical hospitals.” NCT04973462 ↗ “Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days.” NCT00980109 ↗ “the antiviral oseltamivir was evaluated in two prospective open-label studies.” PMID 26042486 ↗ Jul 2015 “Oseltamivir will be administered as oral suspension BID for 5 days.” NCT03629184 ↗ “Post-exposition prophylaxis with oseltamivir or placebo.” NCT01053377 ↗ “* Oseltamivir 150 mg q 12 hours for 10 days ;” NCT04530422 ↗ “oseltamivir 75 mg bid orally for 5 days” NCT03900988 ↗ |
| Known as | Agucort | ChEMBL registry synonym — accepted as the source's own label CHEMBL1229 ↗ |
| Known as | Ebilfumin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1229 ↗ |
| Known as | GS 4104 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1229 ↗ |
| Known as | GS-4071 ETHYL ESTER | ChEMBL registry synonym — accepted as the source's own label CHEMBL1229 ↗ |
| Known as | HEC116094 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04982913 ↗ |
| Known as | Oseltamivir (as phosphate) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1229 ↗ |
| Known as | oseltamivir phosphate | “Oseltamivir phosphate capsule (tamiflu) (98.5mg/capsule, equals to 75mg oseltamivir, license number J20090076)” NCT02662426 ↗4“Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral” NCT06057103 ↗ “75 mg oral oseltamivir phosphate capsules twice daily” PMID 40489986 ↗ Jun 2025 |
| Known as | Oseltamivir Phosphate Capsules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02989012 ↗ |
| Known as | Oseltamiviri phosphas | ChEMBL registry synonym — accepted as the source's own label CHEMBL1229 ↗ |
| Known as | OSL | “A triple-combination antiviral drug (TCAD) regimen consisting of amantadine (AMT), oseltamivir (OSL) and ribavirin (RBV) demonstrated good efficacy in an animal model.” PMID 23264438 ↗ Dec 2012 |
| Known as | OST (oseltamivir) | “OST (oseltamivir)” NCT01610245 ↗ |
| Known as | OSV | “oseltamivir (OSV)” NCT02469298 ↗ |
| Known as | RO 64-0796/002 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1229 ↗ |
| Known as | Ro 64-0796/GS4104 | “The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers.” PMID 10934667 ↗ Aug 2000 |
| Known as | RO 640796 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1229 ↗ |
| Known as | Tamiflu | “An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir (Tamiflu®) in the Treatment of Infants 0 to <12 Months of Age With Confirmed...” NCT00988325 ↗17“Oseltamivir (Tamiflu - manufactured by Roche) formulation is available as 75 mg Capsule and as powder for oral suspension.” NCT02927431 ↗ “Oseltamivir phosphate capsule (tamiflu) (98.5mg/capsule, equals to 75mg oseltamivir, license number J20090076)” NCT02662426 ↗ “Oseltamivir (Tamiflu®) is not an experimental drug, but is US Federal Drug Administration (FDA) approved” NCT00707941 ↗ “Oseltamivir (Tamiflu) Dosing Strategies for Use During Influenza Prophylaxis (VA01)” NCT00304434 ↗ “Oseltamivir (Tamiflu) is used most often to treat flu” NCT01227967 ↗ “oseltamivir (Tamiflu(Registered Trademark))” NCT00334529 ↗ “Drug: oseltamivir (Tamiflu®)” NCT00391768 ↗ “Oseltamivir (TAMIFLU®)” NCT05648448 ↗ “Drug: Tamiflu (verum)” NCT01053377 ↗ “oseltamivir [Tamiflu]” NCT01980966 ↗ “Oseltamivir (Tamiflu)” NCT00873886 ↗ “oseltamivir [Tamiflu]” NCT00436124 ↗ “oseltamivir [Tamiflu]” NCT00412555 ↗ “oseltamivir [Tamiflu]” NCT01033734 ↗ “oseltamivir [Tamiflu]” NCT01172847 ↗ “Tamiflu (oseltamivir)” NCT01556633 ↗ |
| Action | Inhibit | “potently and specifically inhibits the viral neuraminidases” NCT00298233 ↗ |
| Modality | Small molecule | — CHEMBL1229 ↗ |
| Route | Oral | “Oseltamivir will be administered orally” NCT00298233 ↗ |